Interim data from the ALTITUDE trial evaluated ABBV-RGX-314 in DR patients with a diabetic retinopathy (DR) severity score (DRSS) of 47–65, without center-involving DME, and no recent anti-VEGF treatment [63]. This evidence concerns the gene VEGFA and diabetic retinopathy.